Michael Laffan is Professor of Haemostasis and Thrombosis in the department of haematology.He trained in medicine at the University of Oxford and trained in haematology at the Hammersmith and Royal Free hospitals. His principal research interests are the structure function relationship of von Willebrand factor, in particular the role of glycosylation, and the mechanisms and regulation of thrombin generation. He is director of the Hammersmith Hospital Haemophilia centre and is responsible for postgraduate education in haematology.
et al., 2021, Genetically Proxied Inhibition of Coagulation Factors and Risk of Cardiovascular Disease: A Mendelian Randomization Study., J Am Heart Assoc
et al., 2021, Thromboses and COVID-19: reducing inflammation in addition to thromboprophylaxis, Lancet Rheumatology, Vol:3, ISSN:2665-9913, Pages:E171-E172
et al., 2021, The heparin-von Willebrand factor interaction and conventional tests of haemostasis - the challenges in predicting bleeding in cardiopulmonary bypass, British Journal of Haematology, Vol:192, ISSN:0007-1048, Pages:1073-1081
et al., 2021, Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19, Thrombosis Research: Vascular Obstruction, Hemorrhage and Hemostasis, Vol:201, ISSN:0049-3848, Pages:100-112
et al., 2021, EXAMINATION AND VALIDATION OF A PATIENT-CENTRIC JOINT METRIC: "PROBLEM JOINT"; EMPIRICAL EVIDENCE FROM THE CHESS II DATASET, WILEY, Pages:75-75, ISSN:1351-8216